TARS · NASDAQ · STOCK
Tarsus Pharmaceuticals (TARS) Stock Analysis
$73.09
52W $38.51 – $91.53
59/100
$3.15B
-67.1
0.54
Is TARS Bullish or Bearish?
Mixed.
Innellis AI committee rates Tarsus Pharmaceuticals, Inc. (TARS) Watch with a composite score of 59/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +0.97 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -19.03 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.21) -- balance sheet can absorb a shock. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 105.2% YoY -- genuine top-line momentum — Growth
- Low leverage (debt-to-equity 0.21) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 10.1x prices in significant intangible value — Value
- ROE of only -13.5% -- cheap may mean cheap for a reason — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
59/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 39%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 10.1x prices in significant intangible value
Growth Analyst
bullish
60
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 105.2% YoY -- genuine top-line momentum
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.21) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 59.0 to 59.0.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
38.8
Neutral
MACD Histogram
-0.770
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$61.62
Resistance
$73.54
Bollinger %B
0.17
Inside Bands
Price vs Moving Averages
EMA 9
$74.22
Below
EMA 21
$75.30
Below
EMA 50
$73.43
Below
EMA 200
$67.88
Above
Fundamental Analysis
Valuation
67
Growth
15
Profitability
25
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
-67.1×
P/B Ratio
9.16×
PEG Ratio
-0.80
Dividend Yield
0.00%
52W High
$91.53
52W Low
$38.51
Quality & Growth
ROE
-1934.0%
ROA
-1181.5%
Gross Margin
9059.4%
Operating Margin
-800.5%
Revenue Growth YoY
—
Debt / Equity
0.26
AI Fundamental Assessment
P/E ratio of -67.1 (inexpensive relative to a 15-40x range); Price-to-book of 9.2x; PEG ratio of -0.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -19.3%; Return on assets of -11.8%; Net margin of -7.7%; Gross margin of 90.6%; Current ratio of 3.20 (healthy short-term liquidity); Debt-to-equity of 0.26; Free cash flow per share is positive (1.42); Most recent quarter missed estimates by 145.1%; EPS growth decelerating (+20.0% -> -206.2% QoQ); Analyst estimates falling over recent quarters
Get the Full TARS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →